StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CMMBBullishM&Anews
High materiality8/10

Chemomab-Scipher merger advances, potential SCIP listing with 2028 RA readout

Aug 19, 2026, 8:29 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Near-term merger news plus a defined runway and CVRs create optionality; potential Nasdaq listing adds liquidity/fundamental re-rating; Phase 2 RA readout in 2028 provides a clear fundamental catalyst if positive.

AI summary

What happened, with direct paths to the underlying reporting

Chemomab and Scipher announced a definitive merger valuing the combined company at $150 million, coupled with a $30 million private placement. Nebokitug, a first-in-class anti-CCL24 antibody, targets RA with Phase 2 planned to start in H1 2027 and readout in H1 2028. Contingent value rights may provide up to $50 million in future payments; SCIP is expected to trade on Nasdaq after closing.

  • Chemomab and Scipher advance definitive merger. Nebokitug targets RA in Phase 2.
  • Nebokitug RA Phase 2 begins H1 2027. Readout in H1 2028.
  • Combined value: $150m before $30m private placement; close by year-end 2026.
  • Cash runway through Q1 2027; SCIP Nasdaq listing expected post-close.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event